亚洲社会药学

本期目录

2021年, 第16卷, 第4期　刊出日期：2021-12-20 上一期   

Select

Research on the Differences of Media Reports on COVID-19 Based on Agenda-Setting Theory Zhang Wei, Wei Fuqian, Yang Yue 2021 (4):  281-289.  摘要 ( 585 )   PDF(5847KB) ( 372 )   Objective To study the news reports on COVID-19 through comparing the forwarding volume and posting time of microblogs from the government media and non-government media and exploring the advantages and disadvantages of the two in mastering discourse power in public health emergencies, so to provide a reference for the government department to cope with online public opinion. Methods The GooSeeker data mining tool was used to collect the data of the six microblog accounts that reported the COVID-19 from January 1 to June 15, 2020. Then the data were analyzed from two aspects of microblog forwarding volume and posting time. Results and Conclusion According to the analysis of the forwarding volume data, the government media had a greater influence on the public during the process of COVID-19. The analysis of the news release time showed that the government media and non-government media had similar ability in discourse power on public health emergencies. This paper proposes the following recommendations for government departments to enhance their abilities to cope with online public opinion on public health emergencies, such as releasing information promptly, cultivating opinion leaders, and reporting the fact to avoid public misunderstandings. 相关文章 | 计量指标

Select

Policy Comparison between Shenzhen GPO and Guangdong Medicine Exchange Center Xiang You, Tian Lijuan 2021 (4):  290-294.  摘要 ( 358 )   PDF(785KB) ( 361 )   Objective To put forward some suggestions for improving the procurement policy of Shenzhen Pharmaceutical Group. Methods The literature research and comparative research were used to compare the policies between Guangdong’s centralized drug procurement and Shenzhen Pharmaceutical Group’s procurement so as to analyze their advantages and disadvantages. Results and Conclusion The purchasing model of Shenzhen group purchasing organization (GPO) can ensure the timely supply of medicines. Besides, the cross-regional alliance system helps to achieve a true price-for-quantity exchange, and a market-based price linkage mechanism can effectively reduce drug prices. However, the online drug catalogue of Shenzhen GPO cannot fully cover the actual needs of hospitals for procurement. The market-based price linkage may lead to problems of drug quality or shortage of drugs. Therefore, the number of batches of drugs should be increased online appropriately. Meanwhile, a mechanism must be established to guarantee the supply and quality of low-priced drugs. 相关文章 | 计量指标

Select

Research on the Relationship between Salary Incentives for R&D Personnel and R&D Investment in China’s Pharmaceutical Industry Wang Yuzhuo, Wang Su, Chen Yuwen 2021 (4):  295-304.  摘要 ( 300 )   PDF(901KB) ( 298 )   Objective To explore the relationship between salary incentives for R&D personnel and R&D investment in China’s pharmaceutical industry through an empirical analysis so as to propose suggestions for increasing more R&D investment from the perspective of stimulating R&D personnel. Methods Based on the relevant data of the China’s pharmaceutical industry in the “China High-tech Industry Statistical Yearbook” and other data from the National Bureau of Statistics from 1995 to 2018, co-integration tests was used to construct error correction models and Granger causality tests to explore the relationship between R&D personnel salary incentives and R&D investment. Results and Conclusion There is a long-term balanced relationship between the salary level of R&D personnel in China’s pharmaceutical industry and the investment of R&D. For the per capita salary of R&D personnel increases by 1 unit, the internal expenditure of R&D investment will increase by 2.245 1 units. In the short term, the per capita salary of R&D personnel has a slight negative impact on the internal expenditure of R&D investment. In addition, the salary incentives for R&D personnel have the most significant role in promoting R&D investment after five years of implementation. 相关文章 | 计量指标

Select

Research on the Relationship between the Profitability and R&D Investment of Enterprises of Different Scales in China’s Pharmaceutical Industry Kudireti·shataer , Chen Yuwen 2021 (4):  305-319.  摘要 ( 262 )   PDF(1084KB) ( 127 )   Objective To analyze the relationship between the profitability of pharmaceutical enterprises of different scales and their R&D investment. Methods The data of China’s pharmaceutical manufacturing industry from 1995 to 2016 were selected to establish a vector auto-regression mode, and then an impulse response function and variance decomposition were used to analyze the data. Results and Conclusion For large-scale pharmaceutical enterprises, 1% increase in R&D input will lead to 0.792% increase of their main business profit. For medium-sized enterprises, if their main business profit increases by 1%, their R&D input will increase by 0.965%. Therefore, if their R&D input increases by 1%, their main business profit will increase by 1.036%. The improvement of the profitability of large-scale pharmaceutical enterprises cannot promote the increase of R&D capital investment. But the increase of profitability from medium-sized enterprises can promote the increase of R&D capital investment. As a result, the increase of R&D capital investment of large and medium-sized enterprises can improve corporate profitability. 相关文章 | 计量指标

Select

Identification of Technology Catch-up Path from the Perspective of Technology Leapfrogging Huang Yufeng, Ning Bowen, Yuan Hongmei 2021 (4):  320-328.  摘要 ( 347 )   PDF(3540KB) ( 302 )   Objective To propose a method to identify the shortest catch-up path by using patent data based on the perspective of technology leapfrogging so as to provide a reference for the catch-up strategy formulation by the governments of the developing countries. Methods Firstly, the international patent classification (IPC) co-occurrence network was used to screen key technologies, and the TOP 5 countries and China were located from the aspects of technology life cycle and technological innovation capabilities. Next, the technology development path based on the ordered clustering algorithm and the main IPC number was set up. Finally, the Dijkstra algorithm was applied to identify the shortest catch-up path. Results and Conclusion Applying this method to the current biopharmaceutical industry with the most potential for development, the shortest catch-up paths are found in the selected C12N15, C07K14 and C12Q1 technology fields, proving the feasibility of the method. 相关文章 | 计量指标

Select

Survey of Shanghai Residents’ Perceptions of Buying Prescription Drugs Online#br# Yan Weijie, Li Lingxi, Li Yanran, Min Jie, Zhang Zhixuan, Zhou Yuliang, Huang Jiaoling, Zhang Li 2021 (4):  329-333.  摘要 ( 327 )   PDF(846KB) ( 314 )   Objective To investigate the willingness of Shanghai residents to buy prescription drugs online. Methods By using e-questionnaire, Shanghai residents’ perceptions of online prescription drugs were investigated, and 206 valid questionnaires were collected. Results and Conclusion 96.1% of the respondents knew the correct definition of prescription drugs. 46.6% knew they could buy prescription drugs online. 67.7%, through social media, knew they could buy prescription drugs online. 72.3% knew a medical prescription should be required when buying prescription drugs online. And 83.5% refused to buy prescription drugs online because they were concerned about the quality and safety of drugs. The publicity of online-pharmacies and prescription drugs should be increased in China. Besides, the government supervision should be strengthened in the whole process of service to protect consumers’ rights and benefits. Then, the channels of online purchase must be optimized for customers. Lastly, a medical insurance payment system should be set up for buying prescription drugs online. 相关文章 | 计量指标

Select

Selection Method of Production Enterprises by Large Pharmaceutical Commercial Companies Based on AHP Wang Xinyue, Lin Xiangpeng, Sun Xiaohua, Wang Shuling 2021 (4):  334-342.  摘要 ( 408 )   PDF(902KB) ( 318 )   Objective To study the policies of integrating medical resources and centralized drug procurement in China from 2018 to 2020, and to provide a reference for large pharmaceutical commercial companies to select partners. Methods Analytic hierarchy process (AHP) and fuzzy synthesis evaluation method were used to establish the index evaluation system and assign values to each index. Results and Conclusion According to the questionnaire survey data, the weight of each evaluation index was determined, and the evaluation results were obtained by using the fuzzy synthesis evaluation method. The selection of production enterprises by large pharmaceutical commercial companies includes five first-level indicators and 11 second-level indicators. They can provide a favorable reference for the selection of production enterprises by large pharmaceutical commercial companies against the background of complex pharmaceutical industry. 相关文章 | 计量指标

Select

Research Progress on Dimension and Indicators of Comprehensive Value Assessment of Anti-Tumor Drugs Jia Hanxue, Zhang Fang 2021 (4):  343-351.  摘要 ( 298 )   PDF(1272KB) ( 228 )   Objective To sort out the dimension and indicators of comprehensive value assessment of anti-tumor drugs abroad, and provide a reference for constructing a similar system in China. Methods The keywords such as antitumor drugs, value, assessment, method, and framework were used to search CNKI, WanFang database, VIP database, Embase, PubMed and Web of Science. Results and Conclusion According to the research on the value framework of anti-tumor drugs, 6 first-level dimensions and 8 second-level indicators with common characteristics were summarized. In view of China’s national conditions, this study summarizes the available value judgment dimensions of anti-tumor drugs at home and abroad, so as to learn from international experience and their mature methodologies, and provide ideas for constructing a multi-dimensional value system of anti-tumor drugs in China. 相关文章 | 计量指标

Select

Management of Orphan Drug Reimbursement Abroad and Its Enlightenment to China Ma Jia, Li Xiaoqi, Raela·Abduhilil, Sun Lihua 2021 (4):  352-357.  摘要 ( 337 )   PDF(819KB) ( 319 )   Objective To analyze relevant policies and measures on the management of orphan drug reimbursement in foreign countries to provide a reference for future reimbursement management in China. Methods According to the percentage of health care expenditure in GDP, the completeness of rare disease policies, and the total population, Russia, Australia, and India were selected as the reference. Based on the existing literature, the main content and characteristics of the reimbursement of rare disease drugs were analyzed. Results and Conclusion Russia manages rare diseases in the form of lists. Special rare diseases are reimbursed by federal or regional finances, and ordinary rare diseases are reimbursed by statutory medical insurance funds. Orphan drugs in Australia are included in the pharmaceutical benefits scheme (PBS) and the lifesaving drugs program (LSDP), LSDP provides fully reimbursed drugs for eligible rare disease patients. India’s proposal takes health system sustainability into consideration. China should carry out epidemiological research to legally determine the rare diseases, establish reasonable reimbursement standards, and improve the multi-level reimbursement system. 相关文章 | 计量指标

Select

Study of the Impact of the COVID-19 Pandemic on Health Insurance Fund of Hubei Province in 2020 Zhi Yuanyuan, Dou Lele, Xing Miaomiao, Wang Shuling 2021 (4):  358-369.  摘要 ( 336 )   PDF(967KB) ( 203 )   Objective To provide a reference for future budget of health insurance fund for the COVID-19 pandemic in other parts of China or other major public health events. Meanwhile, it also offers a reference for the government to introduce and adjust the policy of health insurance funds after the pandemic. Methods Models of the income, expenditure and cumulative balance of health insurance fund in Hubei Province in 2020 were established and compared. The former was mainly established and tested using SPSS 26.0 and Excel, while the latter was obtained by inferential analysis. Results and Conclusion The COVID-19 pandemic reduced the income and increased expenditure of the health insurance fund in Hubei Province in 2020, resulting in a deficit. The COVID-19 outbreak has caused a deficit in health insurance fund of Hubei Province in the short term, but in the long term, the outbreak will not have a major impact on the health insurance fund. 相关文章 | 计量指标